Search

everythinglearnresearchcommunity

for

Search:↓

A 23-year-old experiencing severe diffuse thinning after scalp inflammation is considering finasteride as a last resort after stopping minoxidil and using anti-inflammatory medication. Users suggest that inflammation causes temporary shedding and recommend consulting a dermatologist, with some advocating for finasteride as a reliable treatment option.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, specifically the progress made with Pyrilutamide over 15 months. One person suggests using oral Minoxidil or Dutasteride, but another mentions experiencing negative side effects from oral Finasteride.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.

RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

A 21-year-old noticed vellus hair regrowth on their hairline after adopting a healthy lifestyle and meditation, without using treatments like Minoxidil or Finasteride. Other users are skeptical, attributing the regrowth to placebo effects.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

A 26-year-old man with diffuse alopecia is using electric scalp massage, dermastamp, and multivitamins for treatment but is intolerant to finasteride. A dermatologist recommended PRP and mesotherapy with exosomes and dutasteride.

A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

A 22-year-old has been treating hair loss with 1mg finasteride daily, 5% minoxidil nightly, and 0.1% tretinoin nightly for three months, noticing improvements in hair quality. Progress pictures show changes a month apart, starting before treatment.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user has been using Dutasteride for over a year for hair loss and is considering a hair transplant if it doesn't work. Suggestions include adding Minoxidil and microneedling, but some advise against a transplant as the current treatment seems effective.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.